Industry News

The following is an excerpt from a press release from Octapharma. Read the press release in its entirety here.

Octapharma announced that new data on the benefits of Nuwiq in patients with hemophilia A were presented during a scientific symposium at the 27th International Society on Thrombosis and Haemostasis Congress in Melbourne, Australia.

The symposium, entitled 鈥Conveniently Protecting What Matters: Nuwiq (Simoctocog Alfa) in PUPs and Personalised Prophylaxis鈥, focussed on addressing some of the most important clinical needs of people with haemophilia A, and included final data from the NuProtect Study in previously untreated patients (PUPs), which were presented for the first time. The symposium was chaired by Ellis J. Neufeld (St. Jude Children鈥檚 Research Hospital, Memphis, USA).

Larisa Belyanskaya, Head of the Octapharma鈥檚 Haematology International Business Unit stated 鈥We are very pleased to present the final data from the NuProtect study in PUPs, confirming the favourable rate of inhibitor development with Nuwiq reported in the earlier interim analysis.鈥.

Olaf Walter, Board Member at Octapharma, said 鈥The data presented at the symposium build on a broad clinical experience with Nuwiq. The ISTH congress is a key platform for exchanging information in the international hemophilia field and we are proud to present these new and robust data in PUPs, which we believe will help to improve hemophilia A treatment.”


Read the press release in its entirety here.聽

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.